Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials

M. Dowsett*, J. F. Forbes, R. Bradley, J. Ingle, T. Aihara, J. Bliss, F. Boccardo, A. Coates, R. C. Coombes, J. Cuzick, P. Dubsky, M. Gnant, M. Kaufmann, L. Kilburn, F. Perrone, D. Rea, B. Thuerlimann, C. van de Velde, H. Pan, R. PetoC. Davies, R. Gray, M. Baum, A. Buzdar, I. Sestak, C. Markopoulos, C. Fesl, R. Jakesz, M. Colleoni, R. Gelber, M. Regan, G. von Minckwitz, C. Snowdon, P. Goss, Early Breast Cancer Trailists’ Collaborative Group EBCTCG, Petrus Hupperets

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Background the optimal ways of using aromatase inhibitors or tamoxifen as endocrine treatment for early breast cancer remains uncertain.
Original languageEnglish
Pages (from-to)1341-1352
JournalLancet
Volume386
Issue number10001
DOIs
Publication statusPublished - 3 Oct 2015

Fingerprint

Dive into the research topics of 'Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials'. Together they form a unique fingerprint.

Cite this